Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
NCT03641339 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 95
Last updated 2021-12-08
Summary
Background:
Mosquitoes and similar insects called sand flies carry parasites that can cause diseases. These viruses and parasites can spread quickly and be difficult to control. How people s bodies respond to insect bites may affect how they get infected. The response to bites is caused by the immune system, which helps fight off infections. Researchers want to study the immune response in skin to mosquito or sand fly bites and how the response changes after bites on multiple days. This may help researchers develop better vaccines.
Objective:
To study the immune response in skin to certain insect bites and how that changes after bites on multiple days.
Eligibility:
Healthy adults ages 18-64
Design:
Participants will be screened under another protocol. Women must agree to practice effective contraception or abstinence. All participants must agree to not donate blood or use certain lotions or creams on visit days.
Some participants will have 2 visits over a week. Others will have 5 visits over 8 weeks.
All participants will have the following at least once:
Medical history
Physical exam
Blood and urine collected
Mosquito or sand fly feeding. Up to 10 insects will feed on participant s arm for up to 20 minutes. The insects are grown at NIH and do not carry any diseases. The skin will be checked and bites will be treated.
Skin samples taken. The skin will be cleaned and numbed. A tool will remove a small piece of skin from 3 places on the arm.
About a week after the last visit, participants will be called to see how they feel.
Conditions
- Zika
- Dengue
- Malaria
- Chikungunya
- Leishmaniasis
Interventions
- OTHER
-
One vector feeding
Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)
- OTHER
-
Four vector feeding
Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Matthew J Memoli, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-09-05
- Primary Completion
- 2020-05-20
- Completion
- 2020-05-20
Countries
- United States
Study Locations
More Related Trials
-
Malaria Vaccine for Children in Mali
NCT00740090 ·Status: COMPLETED ·Phase: PHASE1
-
Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing
NCT04034264 ·Status: RECRUITING
-
A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya
NCT00666380 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria
NCT00414336 ·Status: COMPLETED ·Phase: PHASE1
-
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
NCT06000514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Attractive Targeted Sugar Bait Trial in Mali
NCT04149119 ·Status: UNKNOWN ·Phase: NA
-
Host Response to Infection and Treatment in Filarial Diseases
NCT00001230 ·Status: RECRUITING
-
Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria
NCT06917040 ·Status: COMPLETED ·Phase: PHASE3
-
Implementation Research of New Dengue Vector Control Tools
NCT00883441 ·Status: COMPLETED ·Phase: NA
-
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
NCT03294161 ·Status: COMPLETED ·Phase: PHASE2
-
Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis
NCT06011343 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil
NCT03106714 ·Status: COMPLETED
-
Clinical Investigation of Infections Due to Leishmanial Parasites
NCT00001169 ·Status: COMPLETED
-
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
NCT03303898 ·Status: COMPLETED ·Phase: NA
-
Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)
NCT01434381 ·Status: COMPLETED ·Phase: PHASE1
-
Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines
NCT00443131 ·Status: COMPLETED ·Phase: PHASE2
-
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
NCT02639299 ·Status: RECRUITING
-
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis
NCT00111553 ·Status: COMPLETED ·Phase: PHASE1
-
A Systems Biology Approach to Malaria Immunity
NCT03014258 ·Status: COMPLETED ·Phase: PHASE1
-
Preventing the Spread of Malaria in Mali
NCT01360112 ·Status: COMPLETED
-
Surveillance for Leishmaniasis Skin Lesions in Mali
NCT00344084 ·Status: COMPLETED
-
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
NCT02544048 ·Status: COMPLETED
-
Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali
NCT02206451 ·Status: COMPLETED
-
Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
NCT02406729 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
ICC-1132 - Candidate Vaccine Against P Falciparum Malaria
NCT00587249 ·Status: COMPLETED ·Phase: PHASE1